MAP2K7 and neoplasm: Notably, HSP90 inhibitors can activate NF-κB signaling via fibroblast stimulation through extracellular vesicles (29), while MEK inhibition may reverse tumor cell dedifferentiation and synergize with BET or FAK inhibitors to overcome adaptive resistance (30).